Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

CFS: Medical Crossfire®: How Do You Use Liquid Biopsies in NSCLC?

CFS: Medical Crossfire®: How Do You Use Liquid Biopsies in NSCLC?

Friday, November 9, 2018
2:10 PM - 3:40 PM

Registration: 1:40 PM - 2:10 PM

New York Marriott Marquis
Julliard Complex (5th Floor)
1535 Broadway
New York, NY 10036
(212) 398-1900


Molecular testing in lung cancer has rapidly advanced to include liquid-based biopsies and multigene panels as standard approaches, providing the opportunity to improve outcomes for your patients with lung cancer. Medical Crossfire®: How Do You Use Liquid Biopsies in NSCLC? will provide you with expert opinion and education on the application of liquid biopsies, including practical advice on interpreting test reports, and ultimately choosing the best therapeutic approaches for your patients through multiple lines of therapy.

This activity features 4 modules, which will discuss standards of care and recent advances in molecular testing. Module 1 will outline the importance of molecular profiling of tumor tissue in treatment decision-making, as well as the strengths and weaknesses of conventional tissue-based testing. In Module 2, current data supporting the different approaches to biopsy and molecular testing will be discussed, including the various technologies that are available. Module 3 will provide participants with real case examples and expert commentary to illustrate the approaches to interpreting the results of molecular tests. Module 4 will address outstanding questions and potential future applications of liquid-based biopsies. This program will provide cutting-edge and practical guidance that can be applied immediately to your clinical practice.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This educational activity is intended for medical oncologists, hematologists, and fellows who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Evaluate the relative strengths and limitations of liquid biopsy against those of conventional tissue biopsy
  2. Describe the scientific foundations of liquid biopsy technology
  3. Differentiate available and emerging testing technologies with respect to sensitivity, specificity, and clinical applications for patients with lung cancer
  4. Appraise clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with lung cancer

Activity Chair

Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC



You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information



Become a Member

Forgot Password?
Calendar of Events
Filter By